DetermaRx™ is a treatment stratification test to identify patients with stage I and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.

~40,000

patients are diagnosed with early-stage non-small cell lung cancer (NSCLC) each year.2

30-50%

of early-stage patients will not survive despite complete surgical resection.3

DetermaRx provides a

better way

to understand which patients may benefit from chemotherapy.

Now paired from the same tissue sample, DetermaRx + EGFR is the complete molecular testing solution in early-stage NSCLC, guiding treatment selection and sequencing of targeted therapy (osimertinib) and adjuvant chemotherapy.

Here’s How DetermaRx Works

DetermaRx

Identify your patients who may benefit from chemotherapy

Icon of checklist

Order

Order DetermaRx for your patient with stage I or IIA non-squamous NSCLC undergoing resection. You may also opt in for EGFR mutation analysis on the same tissue sample if you wish.

Icon of microscope

Test

We analyze the molecular signature of your patient’s tumor tissue to stratify your patient’s risk.

Icon of checklist

Results

Make informed treatment decisions for your patient following surgery.
FREQUENTLY ASKED QUESTIONS

See our

Clinical Evidence

  • DetermaRx is a 14-gene molecular stratification test that has been validated in two independent cohorts with close to 1400 patients.4
  • DetermaRx outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIA non-squamous NSCLC.4
  • Patients identified by DetermaRx as high-risk* and who were treated with adjuvant platinum chemotherapy had 91.7% 5-year disease-free survival compared to 48.9% 5-year DFS for high-risk patients who did not receive chemotherapy.1
  • Significant difference in survival amongst chemotherapy treated vs. untreated high-risk* patients was reinforced in an expanded 250 patient prospective cohort, in which majority of patients were stage IA.5
  • DetermaRx identified high-risk patients who responded to adjuvant chemotherapy, independent of EGFR status.5

 

View Publications

*Test identified intermediate- and high-risk patients were grouped together in this analysis and designated as molecular high-risk.

See our

Clinical Evidence

Photo of Kaiser Validation Cohort graph
Photo of UCSF Treatment Stratification graph
Edgardo Santos, MD, FACP
Florida Precision Oncology

“The integration of testing for targeted therapy, including EGFR mutation status and chemotherapy selection by DetermaRx on the same sample, will enable oncologists to optimize and sequence treatment post-surgery. In my opinion, these two tests together close the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I would feel confident initiating chemotherapy, followed by targeted therapy for the EGFR-positive, DetermaRx high-risk patients I see in my practice.”

Billing & Resources

We are committed to providing accessible, affordable testing for all

Insurance and Eligibility

We accept all insurance on an out-of-network basis. We will contact you if your estimated out-of-pocket cost exceeds $100.

Icon of hands holding inside of a heart shape

Financial Assistance

We realize that each patient’s situation is unique and offer a Patient Assistance Program to assist with the costs of our test.
VIEW FORM

Icon of headset

We’re here to help

Our billing specialists can verify insurance eligibility and answer any questions you have. Please contact us at 1.844.662.6298

Photo of lungs, heart, and cells

Contact Us


    References
    1. Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58.
    2. SEER data.
    3. Chansky, et al. (2017) The IASLC Lung Cancer Staging Project: External validation of the revision of the TNM stage groupings in the eight edition of the TNM classification of lung cancer. J Thorac Oncol 12:1109
    4. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
    5. Woodard, et al. (2020) Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Abstract presented at 2020 North America Conference on Lung Cancer.